Top News in Genetic Testing for Cancer

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup with a chemotherapy-free interval of 90 or more days.

ODAC voted against the favorability of the agent in combination with dexamethasone and pomalidomide or bortezomib in multiple myeloma.